Renee Lichtenstein

A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma

Jennifer E. Amengual, Renee Lichtenstein, Jennifer Kimberly Lue et al. · Blood · 2017 · 134 citations · Full text

Life Sciences, Immunology, Oncology +8

Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial

Owen A. O’Connor, Jennifer Kimberly Lue, Ahmed Sawas et al. · The Lancet Oncology · 2017 · 118 citations · Full text

Medicine, Oncology, Pharmacology +16

First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma

Jennifer E. Amengual, Jennifer Kimberly Lue, Helen Ma et al. · The Oncologist · 2021 · 54 citations · Full text

Medicine, Oncology, Pharmacology +13

The Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) Demonstrates Marked Activity in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL): Results of an International Multi Center Phase I/II Experience

Ahmed Sawas, Joseph M. Connors, John Kuruvilla et al. · Blood · 2015 · 13 citations

Medicine, Oncology, Pharmacology +17